Evidence map›Paper›PMID 41131331›Full record

ArticleEye (London, England)2025

Assessment of the level of harm resulting from glaucoma progression due to review delay.

Richard Stead, Anthony J King

Abstract read
In one paragraph

Article in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Richard SteadNottingham University Hospitals NHS Trust, Eye and Ear, Nose and Throat, Nottingham, UK. Richard.stead7@nhs.net.ORCID http://orcid.org/0000-0002-8815-1123
Anthony J KingNottingham University Hospitals NHS Trust, Eye and Ear, Nose and Throat, Nottingham, UK.ORCID http://orcid.org/0000-0002-3091-911X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesReporting harm in monitoring delay for glaucoma patients is important but current guidance is limited. This study attempts to refine harm assessment using clinician expertise to identify the factors that should be considered in defining monitoring delay related harm.

methodsNational survey of glaucoma specialists through UK & Eire Glaucoma Society.

resultsFor perimetric harm, the importance of the severity of the reference visual field as well as the importance of locational loss (central and inferior visual field) in defining harm, were highlighted. Other factors such as only eye and loss of driving status should also be considered in defining harm. A delay of >50% was considered as the reference point for defining delay causing harm for the majority of respondents. For pre-perimetric delay there was less agreement on level of harm.

conclusionRecognising harm from glaucoma monitoring delay is important. However, it is a difficult process which is largely non-standardised. Harm itself should be defined by clinical deterioration (global and locational visual field loss) and psychological consequences. A strict definition of delay needs to be defined for the purpose of harm reporting. Other factors such as only eyed or loss of independence should also be considered when considering if harm has occurred.

Indexed as

GlaucomaVisual FieldsDisease ProgressionHumansIntraocular PressureSurveys and QuestionnairesVision DisordersVisual Field Tests

Identifiers

PMID41131331
PMCPMC12669703

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.